Protein metabolism in glucagonoma.
Although protein wasting and reduced amino acid concentrations are common findings in glucagonoma patients, the mechanisms underlying these alterations are unclear. Therefore, we studied basal postabsorptive leucine, phenylalanine and tyrosine turnover following L-[D3]-Leucine, L-[D5]-Phenylalanine and L-[D2]-Tyrosine i.v. infusions in one male and one female patient with glucagonoma, compared with healthy control volunteers. Plasma amino acid concentrations were reduced (-40 to 80%, delta >2 SD vs. control subjects) in both patients. Plasma leucine, phenylalanine and tyrosine rates of appearance in patients with glucagonoma were similar to values in the control subjects, except leucine rate of appearence in the female patient with glucagonoma (+ approximately 30%, delta >2 SD). In contrast, the intracellular leucine rate of appearence, reflecting protein degradation, was considerably increased in both patients (+60-80%, delta >2 SD). Phenylalanine hydroxylation was moderately higher only in the male patient with glucagonoma (+ approximately 30%, delta >2 SD). Leucine, phenylalanine and tyrosine clearances (+100-300%), as well as phenylalanine hydroxylative clearance (+75-100%) were also increased in the patients. In conclusion, whole-body protein breakdown is enhanced in patients with glucagonoma compared with healthy control subjects. Phenylalanine hydroxylative clearance is also higher. Reduced plasma amino acid concentrations are probably due, at least in part, to their increased clearance. These alterations could contribute to the determination of the catabolic state of the glucagonoma syndrome.
Barazzoni
R
R
Division of Clinical and Experimental Medicine, University of Padova, Italy.
Zanetti
M
M
Tiengo
A
A
Tessari
P
P
D000328:Adult; D000596:Amino Acids / Q000097:blood / Q000378:metabolism*; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D003903:Deuterium; D005260:Female; D005934:Glucagon / Q000097:blood; D005935:Glucagonoma / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood; D007930:Leucine / Q000008:administration & dosage / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood / Q000378:metabolism*; D010649:Phenylalanine / Q000008:administration & dosage / Q000378:metabolism; D014176:Protein Biosynthesis; D011506:Proteins / Q000378:metabolism*; D012016:Reference Values; D014443:Tyrosine / Q000008:administration & dosage / Q000378:metabolism
D000596:Amino Acids; D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D011506:Proteins; D014443:Tyrosine; D010649:Phenylalanine; D005934:Glucagon; D003903:Deuterium; D007930:Leucine